STERIS Management
Management criteria checks 4/4
STERIS' CEO is Dan Carestio, appointed in Jul 2021, has a tenure of 4.5 years. total yearly compensation is $10.67M, comprised of 10% salary and 90% bonuses, including company stock and options. directly owns 0.057% of the company’s shares, worth $12.77M. The average tenure of the management team and the board of directors is 5 years and 8.4 years respectively.
Key information
Dan Carestio
Chief executive officer
US$10.7m
Total compensation
| CEO salary percentage | 9.97% |
| CEO tenure | 4yrs |
| CEO ownership | 0.06% |
| Management average tenure | 5yrs |
| Board average tenure | 8.4yrs |
Recent management updates
Recent updates
Is There Now An Opportunity In STERIS plc (NYSE:STE)?
Jul 06
Is Now The Time To Put STERIS (NYSE:STE) On Your Watchlist?
May 23Is There An Opportunity With STERIS plc's (NYSE:STE) 33% Undervaluation?
May 07Is STERIS (NYSE:STE) A Risky Investment?
Apr 19Risks To Shareholder Returns Are Elevated At These Prices For STERIS plc (NYSE:STE)
Apr 01Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'
Mar 22Is Now An Opportune Moment To Examine STERIS plc (NYSE:STE)?
Feb 06STERIS plc (NYSE:STE) Shares Could Be 41% Below Their Intrinsic Value Estimate
Jan 19STERIS (NYSE:STE) Has A Pretty Healthy Balance Sheet
Jan 01STERIS plc's (NYSE:STE) Popularity With Investors Is Clear
Dec 14Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
Nov 18What Does STERIS plc's (NYSE:STE) Share Price Indicate?
Oct 19Is STERIS (NYSE:STE) A Risky Investment?
Oct 01Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued
Sep 16Earnings Tell The Story For STERIS plc (NYSE:STE)
Sep 13
Robust Revenue Growth And Expanding Margins In The Medical Equipment Sector
Strong start to the fiscal year and gross margin improvements suggest underappreciated growth momentum and potential for expanding net margins.Steris: Q2 Numbers Solidify Buy Thesis
Aug 13STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 59% Above Its Share Price
Aug 08Steris: Moving On, Losing Its Teeth
Apr 14Steris: Strong Healthcare Products Growth Coupled With Weak AST Business
Feb 17Steris: Comprehensive Sterilization Portfolios Tailored To Procedure Volumes
Nov 08Steris: Remains On Track For Strong Fiscal '24, Added Upsides From Operating Leverage
Sep 01Steris: Continuing To Grow The Product Lineup
Jun 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | US$11m | US$1m | US$610m |
| Dec 31 2024 | n/a | n/a | US$617m |
| Sep 30 2024 | n/a | n/a | US$591m |
| Jun 30 2024 | n/a | n/a | US$561m |
| Mar 31 2024 | US$10m | US$1m | US$551m |
| Dec 31 2023 | n/a | n/a | US$1b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$576m |
| Mar 31 2023 | US$8m | US$970k | US$557m |
| Dec 31 2022 | n/a | n/a | -US$28m |
| Sep 30 2022 | n/a | n/a | -US$8m |
| Jun 30 2022 | n/a | n/a | US$377m |
| Mar 31 2022 | US$6m | US$767k | US$285m |
| Dec 31 2021 | n/a | n/a | US$279m |
| Sep 30 2021 | n/a | n/a | US$250m |
| Jun 30 2021 | n/a | n/a | US$286m |
| Mar 31 2021 | US$3m | US$542k | US$397m |
| Dec 31 2020 | n/a | n/a | US$433m |
| Sep 30 2020 | n/a | n/a | US$424m |
| Jun 30 2020 | n/a | n/a | US$413m |
| Mar 31 2020 | US$2m | US$522k | US$408m |
| Dec 31 2019 | n/a | n/a | US$393m |
| Sep 30 2019 | n/a | n/a | US$336m |
| Jun 30 2019 | n/a | n/a | US$319m |
| Mar 31 2019 | US$2m | US$482k | US$304m |
Compensation vs Market: Dan's total compensation ($USD10.67M) is about average for companies of similar size in the US market ($USD13.61M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
CEO
Dan Carestio (52 yo)
Mr. Daniel A. Carestio, also known as Dan, serves as the Chief Executive Officer & President at STERIS plc since July 29, 2021. He had been Senior Vice President and Chief Operating Officer at STERIS plc s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4yrs | US$10.67m | 0.057% $ 12.8m | |
| Senior VP & CFO | 17.3yrs | US$3.31m | 0.048% $ 10.8m | |
| Senior VP | 12yrs | US$2.94m | 0.034% $ 7.7m | |
| SVP & Chief Human Resources Officer | 5yrs | US$1.89m | 0.011% $ 2.5m | |
| Senior VP & President of Healthcare | 5.9yrs | US$2.22m | 0.012% $ 2.6m | |
| VP & Chief Accounting Officer | 8.5yrs | no data | 0.0044% $ 990.3k | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior VP & GM of Life Sciences | 5yrs | no data | 0.0096% $ 2.1m | |
| Senior VP & GM of Dental | 4.1yrs | US$1.92m | 0.0065% $ 1.4m | |
| Senior VP & GM of AST | 1.4yrs | no data | 0.0035% $ 791.4k | |
| VP & Corporate Treasurer | 7.9yrs | no data | 0.0069% $ 1.5m | |
| CEO Emeritus & Senior Advisor | 4yrs | US$1.16m | no data |
Experienced Management: STE's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.5yrs | US$10.67m | 0.057% $ 12.8m | |
| Independent Director | 17.3yrs | US$353.90k | 0.032% $ 7.1m | |
| Independent Chairman of the Board | 20yrs | US$503.87k | 0.023% $ 5.1m | |
| Independent Director | 21.8yrs | US$348.79k | 0.027% $ 6.1m | |
| Independent Director | 20.3yrs | US$349.85k | 0.0095% $ 2.1m | |
| Independent Director | 9.7yrs | US$349.92k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$342.35k | 0% $ 0 | |
| Independent Director | 7.2yrs | US$336.35k | 0.00030% $ 67.1k | |
| Independent Director | 5yrs | US$342.30k | 0.00059% $ 131.9k | |
| Independent Director | 2.2yrs | US$334.80k | no data |
Experienced Board: STE's board of directors are considered experienced (8.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/25 14:12 |
| End of Day Share Price | 2025/07/25 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
STERIS plc is covered by 26 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Owczarski | Avondale Partners |
| Michael Polark | Baird |
| Erin Wilson Wright | BofA Global Research |